Real-World data on ripretinib for advanced GIST: what does it mean for patients?
NCT ID NCT06619275
First seen Dec 08, 2025 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This completed observational study in Germany followed 10 patients with advanced gastrointestinal stromal tumor (GIST) who had already tried three or more prior treatments. Researchers tracked how ripretinib affected their quality of life and disease control in everyday clinical practice. The goal was to gather real-world information on the drug's benefits and safety outside of a controlled trial setting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIST - GASTROINTESTINAL STROMAL TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Praxis für interdisziplinäre Onkologie und Hämatologie
Freiburg im Breisgau, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ripretinib (a kinase inhibitor drug)
What this could lead to
If successful, this study could provide real-world evidence on how ripretinib affects quality of life and disease control in advanced GIST patients.
What could go wrong
This is a small observational study (10 participants) with no control group, so results may not apply broadly. It does not test a new treatment, only observes routine care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.